Related Experiment Video
Updated: Apr 22, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
[Tuberculosis: relevance of isoniazid dosage in prevention of liver side effects]
Lucie Negri1, Jean Le Grusse2, Patrick Séraissol1
1Laboratoire de pharmacocinétique et toxicologie clinique, Hôpital Purpan, Institut fédératif de biologie (IFB), Toulouse, France.
Objective:
Several recent studies have established a correlation between NAT2 polymorphism and hepatotoxicity induced by isoniazid. The objective of this work was to assess the place of isoniazid dosage, marker of acetylation phenotype, in clinical practice in the department of Haute-Garonne.
Methods:
Data from reportable disease of tuberculosis and the results of isoniazid dosage performed at the pharmacokinetics and clinical toxicology laboratory were used during the period 2009-2012.
Results:
The current practice of dosage is far from being systematical: only 3.9% of patients who developed tuberculosis have benefited from isoniazid dosage. The isoniazid initial posology was adapted to the acetylation capacity for only 33.3% of patients.
Conclusion:
A decision tree was realized and used to identify populations (low metabolism) liable to benefit from isoniazid dosage.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Inhibitors of Viral Protein Synthesis
Drug toxicity: Idiosyncratic Reactions

